10-Q · May 8, 2026
Oragenics reported a challenging Q1 2026 with no revenue generated, maintaining an EPS of -11.32. Management highlights a recent licensing agreement with Sigyn Therapeutics as a strategic move to enhance their neurology…
Earnings analysis · 10-Q
OGEN earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement or segment results, so current-period revenue, margins, EPS, liquidity balances and free cash flow cannot be quantified…
Read full summary
The supplied 10-Q extract does not include the income statement, balance sheet, cash-flow statement or segment results, so current-period revenue, margins, EPS, liquidity balances and free cash flow cannot be quantified from the filing text provided. The most material disclosed developments are the reduction of the Series H conversion price to $1.00, the company’s stated need for additional capital and going-concern uncertainty, and the pause of the Sigyn transaction. The company also faces an Odyssey-related discovery proceeding after its motion to dismiss was denied on July 13, 2026.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Controls assessed as effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Company contests Odyssey-related discovery
The company appealed the denial of its motion to dismiss the Bill of Discovery and filed a response on August 3, 2026, asserting affirmative defenses. The company states that it believes the matter is without merit and intends to continue contesting it.
-
Sigyn transaction currently paused
The company has paused Sigyn negotiations and is instead focusing on ONP-002 and capital-raising efforts. The previously contemplated transaction involved 3,250,000 shares of new preferred stock convertible into 3,250,000 common shares, although the company is not currently pursuing it.
What to watch
-
Series H anti-dilution creates dilution risk
The Series H Preferred Stock conversion price was adjusted from the initial $2.50 to $1.00 per share after the company issued common stock below the then-current conversion price on March 13, 2026. Because the anti-dilution provision has no floor price, the number of common shares issuable upon conversion is indeterminate and could materially increase dilution.
-
Additional financing is required
The company states that its current cash, cash equivalents and short-term investments are insufficient to fully implement its strategy and sustain operations. It anticipates additional capital will be required and notes that its auditor has expressed substantial doubt about its ability to continue as a going concern.
-
Warrant and preferred-stock overhang
The company states that Series H Warrants are exercisable upon issuance, expire five years from issuance and have a $25 per-share exercise price. The related preferred stock is currently convertible at $1.00 per common-share conversion price, with each $25 stated-value preferred share convertible into approximately 25 common shares, creating potential future dilution and financing uncertainty.
Management's outlook
No quantitative revenue or EPS outlook is provided in the supplied 10-Q extract. The filing states the company has paused discussions regarding the Sigyn transaction and is focusing on ONP-002 and capital raising efforts.
Earlier filings 4
10-Q · November 7, 2025
Oragenics reported a Q3 net loss of $3,066,589 (quarter EPS $(1.96)) and a nine‑month net loss of $7,555,617, driven by R&D of $930,894 and G&A of $2,192,879 for the quarter. Liquidity materially improved: cash was…
10-Q · August 8, 2025
Oragenics reported no product revenue and a net loss of $2,272,035 for Q2 2025 (six months net loss $4,489,028). Operating expenses declined year-over-year (R&D $449,679 vs $906,779; G&A $1,264,523 vs $1,399,221) and…
10-Q · May 9, 2025
Oragenics reported no revenue and a net loss of $2,216,993 (basic and diluted loss per share $(0.12)) for the three months ended March 31, 2025. Cash strengthened to $3,421,078 at quarter end after $2,635,330 of net…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.